ArticleVirchows Archiv : an international journal of pathology2018
The landscape of genetic alterations in ameloblastomas relates to clinical features.
Article in Virchows Archiv : an international journal of pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Clinical Utility of Molecular Testing in Ameloblastoma: A Systematic Review with Functional Meta-synthesis and Exploratory Meta-analysis.Head and neck pathology · 2026Pooled it
- Genetic Profile of Adenomatoid Odontogenic Tumor and Ameloblastoma. A Systematic Review.Frontiers in oral health · 2021Pooled it
- Phase II Study of Copanlisib in Patients With Tumors WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Hybrid/collision ameloblastoma-ameloblastic fibroma: a case with molecular features supporting a tumor-in-tumor model.Virchows Archiv : an international journal of pathology · 2026Article
- Unicystic ameloblastoma of the maxillary anterior region: Clinical challenges and outcomes.Radiology case reports · 2026Article
- Epidemiology and Clinicopathologic Features with Prognostic Implications of Conventional Ameloblastoma: A 22-Year Retrospective Study.Head and neck pathology · 2026Article
- Review
- Association ofJournal of dental sciences · 2026Article
- Spatially resolved transcriptomics identifies epithelial-specific oncogenic signaling networks in ameloblastoma.Journal of dental sciences · 2026Article
- Integrating genotype-phenotype correlations into the diagnostic workflow of odontogenic tumors and cysts: insights from a 69 lesion cohort.Clinical oral investigations · 2025Article
- Ameloblastic Carcinoma: A 40-Year Scoping Review of the Literature.Current issues in molecular biology · 2025Review
- Clinicopathological and Immunohistochemical Risk Predictors for Ameloblastoma Recurrence.Head and neck pathology · 2025Observational
- Durable disease regression with copanlisib treatment in PI3K-mutated metastasizing ameloblastoma: A case report.Rare tumors · 2025Article
- Article
- Factors Associated with Recurrence of Ameloblastoma: A Scoping Review.Head and neck pathology · 2024Article
- Review
- Association of MDM2 Overexpression in Ameloblastomas withInternational journal of molecular sciences · 2024Article
- Efficiency of B-RAF-/MEK-inhibitors in B-RAF mutated Ameloblastoma: Case report and review of literature.Heliyon · 2023Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ameloblastoma is a mostly benign, but locally invasive odontogenic tumor eliciting frequent relapses and significant morbidity. Recently, mutually exclusive mutations in BRAF and SMO were identified causing constitutive activation of MAPK and hedgehog signaling pathways. To explore further such clinically relevant genotype-phenotype correlations, we here comprehensively analyzed a large series of ameloblastomas (98 paraffin block of 76 patients) with respect to genomic alterations, clinical presentation, and histological features collected from the archives of three different pathology centers in France, Germany, and Turkey. In good agreement with previously published data, we observed BRAF mutations almost exclusively in mandibular tumors, SMO mutations predominantly in maxillary tumors, and single mutations in EGFR, KRAS, and NRAS. KRAS, NRAS, PIK3CA, PTEN, CDKN2A, FGFR, and CTNNB1 mutations co-occurred in the background of either BRAF or SMO mutations. Strikingly, multiple mutations were exclusively observed in European patients, in solid ameloblastomas and were associated with a very high risk for recurrence. In contrast, tumors with a single BRAF mutation revealed a lower risk for relapse. We here establish a comprehensive landscape of mutations in the MAPK and hedgehog signaling pathways relating to clinical features of ameloblastoma. Our data suggest that ameloblastomas harboring single BRAF mutations are excellent candidates for neo-adjuvant therapies with combined BRAF/MEK inhibitors and that the risk of recurrence maybe stratified based on the mutational spectrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.